Edward Jung, co-founder and chief technology officer, of Intellectual Ventures, has been out talking about how his company—which was recently described as among Silicon Valley’s most hated—is playing a long game to attack the big problems confronting the world... Read more »
Sure, smartphones let people make calls, but text messages often dominate communication these days.
A duo who previously worked at Google Creative Lab in New York developed an app they believe will inject voice back into the conversation.
Brooklyn-based Cord Project... Read more »
San Diego-based Astute Medical, founded in 2007 to identify and validate protein biomarkers that can be used to improve the diagnosis of high-risk medical conditions, says the FDA has cleared its new test for detecting acute kidney injury (AKI).
In... Read more »
Detroit Pistons fans of a certain age will always have a place for MC Hammer in their hearts, since his song “U Can’t Touch This” will forever be associated with the triumphant Bad Boys era of the early 1990s.
But... Read more »
John Maraganore opened up an envelope in 1994 that changed his life. Inside were the results of the pivotal study of an anticoagulant drug Maraganore had created in the lab. It was the star prospect for Maraganore’s employer, Biogen. If the... Read more »
John Maeda stands at the intersection of design and technology—and attracts a bit of a cult following. He’s the first Design Partner at Kleiner Perkins, the venture capital firm that has backed companies from Amazon to Genentech to WebMD. Previously, he... Read more »
There are always surprises—both good and bad—in a volatile sector like biotech. A big deal can seemingly come out of nowhere, for instance, and send a company’s stock flying. That was the top story in East Coast biotech this week, but... Read more »
Techstars is making a new pitch to entrepreneurs—satisfaction guaranteed, or your equity back.
The startup accelerator, based in Boulder, CO, invests $18,000 in its startups in exchange for 6 percent of their equity. Techstars also offers each startup a $100,000 convertible... Read more »
It wasn’t too long ago that Merck (NYSE: MRK) was well behind Bristol-Myers Squibb (NYSE: BMY) in the race to bring the first so-called PD-1 inhibitor—a new class of cancer drugs that harness the power of the immune system—to... Read more »